The 17,000-woman study, led by Peking University Shenzhen Hospital, sets three world records and integrates PHASiFY™ DNA concentration technology with AI-powered diagnostics to advance scalable, non-invasive screening in line with WHO’s 2030 elimination goals....
The study applies PHASE Scientific’s proprietary PHASiFY urine-based DNA concentration technology...
Yang Huang, Head of China Healthcare Research at J.P. Morgan, unpacks how favourable policies, demographic shifts, and global collaborations are shaping the future of biopharma and medtech investment in China. ...
XS LLM integrates multimodal capabilities, image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning ...
The study will examine the influence of human-AI collaboration models on consumer adoption...
One-Time Income Release and Improved Gross Margins Strengthen Financials...
AI Empowers Medical Institution Alliances to Strengthen New Quality Productive Forces...
In the first half of 2025, Fosun’s four core subsidiaries generated a total revenue of RMB63.61 billion...
Revenue up 5.8 per cent to HK$876.5 million, Profit up 3.8 per cent to HK$163.4 million...
Photon-counting CT (PCCT) is considered a breakthrough in next-generation imaging...
